Drug Index

Cannabidiol

 
print

Mechanism :

The exact anticonvulsant mechanism of action of cannabidiol is unknown; however, it does not appear to involve its effects on cannabinoid receptors.


Indication :

• Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients =2 years of age.


Contraindications :

Hypersensitivity to cannabidiol or any component of the formulation.


Dosing :

≥2 years and Adolescents: Oral: Initial: 2.5 mg/kg twice daily; increase in weekly. increments of 2.5 mg/kg twice daily to a maximum dosage of 10 mg/kg twice daily.


Adverse Effect :

Drowsiness, lethargy, sedation, sleep disorder, skin rash, weight loss, anorexia, diarrhea, anemia, increased serum AST & ALT, infection, viral infections, asthenia.


Interaction :

CYP2C19 Inducers: May decrease the serum concentration of Cannabidiol.
CYP2C19 Inhibitors: May increase the serum concentration of Cannabidiol.
CYP3A4 Inducers: May decrease the serum concentration of Cannabidiol.
CYP3A4 Inhibitors: May increase the serum concentration of Cannabidiol.
Valproate Products: May enhance the hepatotoxic effect of Cannabidiol.


07/14/2019 19:31:27 Cannabidiol
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0